论文部分内容阅读
目的观察30例重型肝炎患者经非生物型人工肝支持系统(NBALSS)治疗后的转归,探讨NBALSS治疗重型肝炎的临床疗效和安全性。方法 30例患者在常规药物治疗基础上联合NBALSS治疗,并设对照组20例常规药物治疗,比较NBALSS组和对照组的治疗效果,同时观察NBALSS治疗后的不良反应。结果 30例患者经NBALSS治疗后临床症状多有明显改善,ALT、AST、TBIL、Cr均降低(p<0.05),ChE、PTA均升高(p<0.05);对照组常规治疗1周后,ALT、AST、TBIL、Cr、ChE、PTA无明显改变(p>0.05);30例患者最终基本治愈及好转出院23例(76.7%),死亡7例(23.3%);与对照组相比,死亡率明显下降(p<0.05),有统计学意义。NBALSS组68例次治疗后仅有12例次出现不良反应,总发生率为17.6%。结论 NBALSS治疗能有效地改善患者的临床症状和实验室指标,降低重型肝炎的死亡率,并且不良反应发生少,对重型肝炎有肯定的辅助支持治疗作用。
Objective To observe the outcome of 30 patients with severe hepatitis treated by non-biologic artificial liver support system (NBALSS) and discuss the clinical efficacy and safety of NBALSS in the treatment of severe hepatitis. Methods Thirty patients were treated with NBALSS on the basis of routine drug therapy. Twenty patients in the control group were treated with conventional drugs. The therapeutic effects of NBALSS and control groups were compared, and the adverse reaction after NBALSS treatment was observed. Results The clinical symptoms of 30 patients were significantly improved after treatment with NBALSS, ALT, AST, TBIL, Cr were decreased (p <0.05), ChE and PTA were increased (p <0.05); control group after 1 week of conventional treatment, ALT, AST, TBIL, Cr, ChE and PTA had no significant change (p> 0.05). Thirty patients (76.7%) were ultimately cured and discharged after operation, and 7 patients died (23.3% Mortality decreased significantly (p <0.05), with statistical significance. In the NBALSS group, there were only 68 adverse reactions after 12 treatments, with a total incidence of 17.6%. Conclusion NBALSS treatment can effectively improve the patient’s clinical symptoms and laboratory parameters, reduce the mortality rate of severe hepatitis, and fewer adverse reactions, there is a definite adjuvant supportive treatment of severe hepatitis.